BIOTECH SQUIRE
Use Cases

Four Situations Where Partnering Structure Changes the Outcome.

Each scenario below follows the same path: the operational bottleneck, the governance structure Biotech Squire puts in place, and the outcome for the executive team.

01 BIO International Convention · BIO-Europe · J.P. Morgan Healthcare Week · partneringONE · BIO One-on-One Partnering

Post-Conference Partnering Consolidation & Follow-Up

STEP 1

The Bottleneck

After a major partnering conference, requests and replies are scattered across inboxes, portal messages, and meeting notes from the conference week and its online partnering portals. Warm counterparties quietly go cold while the team returns to the lab.

STEP 2

The Governance Structure

Threads from conferences and from portals such as partneringONE and BIO One-on-One Partnering are consolidated, manually filtered of non-partnering noise, and placed into a structured follow-up queue by asset and counterparty.

STEP 3

The Executive Outcome

Leadership follows up while delegate attention is still active, with a clear owner and next action for every conversation that began at the event.

02 Active Board of Directors

Boardroom Partnering Visibility Without Weekend Assembly

STEP 1

The Bottleneck

Ahead of a board meeting, status is reconstructed from fragmented spreadsheets and memory during late evenings and weekends, and the result is out of date by the time it is presented.

STEP 2

The Governance Structure

Each asset and counterparty has a unified deal profile with a defined stage, a clear next-action owner (Active — Ball in Our Court or Active — Ball in Pharma's Court), and concise board-ready reporting views.

STEP 3

The Executive Outcome

Directors receive a consistent, current picture of the partnering pipeline, and the CEO spends preparation time on strategy instead of reconciliation.

03 Hard Pass vs. Conditional Pass — Future Data Trigger

Tracking Conditional Passes & "Future Data" Triggers

STEP 1

The Bottleneck

A pharma scout says "come back when you have the next dataset," and the detail lives in one person's inbox. Months later, nobody recalls which experiment, tox readout, or milestone was requested.

STEP 2

The Governance Structure

Responses are separated into Hard Pass and Conditional Pass — Future Data Trigger. For conditional passes, the exact experiment, readout, or milestone the scout requested is captured alongside the counterparty.

STEP 3

The Executive Outcome

Leadership re-engages the right counterparties at the precise window when new data arrives, and closed doors stay documented rather than rediscovered.

04 NIH SBIR/STTR · Horizon Europe / EIC Accelerator

Demonstrating Commercial Discipline for Series A Diligence

STEP 1

The Bottleneck

Grant-funded and pre-board CEOs have real pharma engagement but no organized record of it. When specialized biotech investors ask about commercial readiness, the evidence is hard to assemble and harder to trust.

STEP 2

The Governance Structure

Pharma engagement is captured as an auditable institutional record: stage progression, champion continuity at each counterparty, and patterns in pass reasons over time.

STEP 3

The Executive Outcome

The team enters Series A diligence with a documented, consistent partnering track record that demonstrates commercial process discipline.

See Which Scenario Fits Your Team.

Book a 15-minute introductory call to discuss your current partnering workflow.

Book a Call